Source: Recce Pharmaceuticals
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Recce Pharmaceuticals (RCE) has released positive safety data from its second cohort of subjects for its Phase I intravenous clinical trial of RECCE 327 (R327)
  • R327 is designed to treat serious bacterial infections including sepsis.
  • The second cohort demonstrated safety and tolerability among seven healthy male subjects who were intravenously dosed with 150mg of R327
  • An independent safety committee has approved an increase in dosage to 500mg in the third cohort
  • Shares were trading 2.69 per cent higher today at $1.34 at the end of the trading day

Recce Pharmaceuticals (RCE) has released positive safety data from its second cohort of subjects for its Phase I intravenous clinical trial of RECCE 327 (R327).

R327 is designed to treat serious bacterial infections including sepsis.

The second cohort demonstrated safety and tolerability among seven healthy male subjects who were intravenously dosed with 150mg of R327.

There were no clinically significant changes in vital signs, clinical, adverse events, or laboratory parameters.

Based upon the clinical data readouts, an independent safety committee has approved a tenfold increase from the initial dosing in cohort one (50mg) or a threefold increase from cohort two (150mg).

Cohort three will consist of seven to ten healthy subjects who will receive dosage of R327 at 500mg.

Subjects are expected to be recruited this week and dosed immediately at Adelaide’s CMAX clinical trial facility.

Chief Executive Officer James Graham said he is pleased with the results.

“We are pleased to see R327 (150mg) successfully tolerated as an intravenous infusion in Cohort Two subjects,” he said.

“Having successfully cleared two dosing levels (50mg and 150mg) we look forward to embarking upon this next significant milestone.”

The study is on track to have all Phase I dosing complete by the second quarter of this year.

Shares were trading 2.69 per cent higher today at $1.34 at the end of the trading day.

RCE by the numbers
More From The Market Herald
Countplus (ASX:CUP) - Incoming CEO, Hugh Humphrey

" Hugh Humphrey appointed CEO of Countplus (ASX:CUP)

Investment services company CountPlus (ASX:CUP) has appointed Hugh Humphrey as the company's CEO, effective July 1.

" ASX employee tests positive for Covid-19

The ASX says an employee has contracted Covid-19.

" ASIC launches official investigation into ASX market outage

The ASX has confirmed today it is officially under investigation from the Australian Securities and Investments…

" ASX sheds more light on last week’s market tech failure

The Australian Securities Exchange has shed some more light on the nature of last week's market…